Ginkgo Bioworks Holdings (DNA) Total Non-Current Liabilities (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Total Non-Current Liabilities for 7 consecutive years, with $553.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities fell 7.79% year-over-year to $553.4 million; the trailing twelve-month figure through Jun 2026 stood at $553.4 million (down 7.79% YoY), and the FY2025 full-year result was $588.2 million, down 8.78% from the prior year.
• Total Non-Current Liabilities slipped to $553.4 million in Q2 2026 per DNA's latest filing, from $568.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $780.3 million in Q1 2023 and bottomed at $391.1 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $611.0 million across 5 years, with a median of $606.2 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 535.75% in 2022, then fell 29.55% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $771.9 million in 2022, then dropped by 29.55% to $543.8 million in 2023, then increased by 18.59% to $644.8 million in 2024, then retreated by 8.78% to $588.2 million in 2025, then slipped by 5.92% to $553.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $553.4 million, $568.2 million, and $588.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.